PubMed
Hexarelin, a synthetic growth hormone-releasing peptide, vs GHRH in GH-deficient adults
Ghigo et al., 1996
GH SecretagoguesResearch OnlyB
Hexarelin
Examorelin
Hexarelin (examorelin) is a synthetic hexapeptide GHRP with the highest GH-releasing potency among the GHRP class. Uniquely among GH secretagogues, hexarelin has demonstrated direct cardioprotective effects through CD36 receptor binding that are independent of GH release — making it of research interest for cardiac protection applications. Research use only; not FDA-approved.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 98
- Activity
- 54
Overall check-ins
Trackers & reports
Overview
About Hexarelin
Hexarelin (examorelin) is a synthetic hexapeptide GHRP with the highest GH-releasing potency among the GHRP class. Uniquely among GH secretagogues, hexarelin has demonstrated direct cardioprotective effects through CD36 receptor binding that are independent of GH release — making it of research interest for cardiac protection applications. Research use only; not FDA-approved.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Examorelin
- Self-reports
- 24
Community
What 24 users report
24 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
143
Sleep
143
Energy
78
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
5
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
84
200–400
59
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 148 days · Based on 23 repeat reporters
Research
Cited research (5)
Source
PubMed
Hexarelin provides cardioprotective effects in rats
Bisi et al., 2001
ClinicalTrials.gov
Hexarelin studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
We are ageing
Kolovou et al., 2014
PubMed
The cardiovascular action of hexarelin
Mao et al., 2014
Tools
Explore more
Explore
More ways to learn about Hexarelin from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about Hexarelin?
This page summarizes 24 anonymized self-reports from PeptIQ users who track Hexarelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Hexarelin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Hexarelin?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Hexarelin safe to use?
This wiki does not assess safety or recommend use. Hexarelin is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Hexarelin?
Research, primarily in animal models, suggests Hexarelin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Hexarelin?
Hexarelin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Hexarelin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Hexarelin?
The safety and effectiveness of Hexarelin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Hexarelin?
While there are over 200 published studies on Hexarelin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source